Cite
HARVARD Citation
Luke, J. et al. (2022). Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 399 (10336), pp. 1718-1729. [Online].